The promise of adoptive cellular immunotherapies in hepatocellular carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–8.
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, Greten TF, McGlynn KA. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122:1757–1765.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Sun J-Y, Yin T, Zhang X-Y, Lu X-J. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol. 2019;234:12116–12121.
   Web of Science ®Google Scholar
• Copur MS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:2498–authorreply2498–9.
   PubMedGoogle Scholar
• Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616.
   PubMed Web of Science ®Google Scholar
• Menon S, Shin S, Dy G. Advances in cancer immunotherapy in solid tumors. Cancers (Basel). 2016;8:106.
   PubMed Web of Science ®Google Scholar
• D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9:282.
   PubMed Web of Science ®Google Scholar
• Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother. 2010;33:211–218.
   PubMed Web of Science ®Google Scholar
• Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681–700.
   PubMed Web of Science ®Google Scholar
• Kim HY, Park J-W. Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. Therap Adv Gastroenterol. 2017;10:805–814.
   PubMed Web of Science ®Google Scholar
• Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27:407–414.
   PubMed Web of Science ®Google Scholar
• Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415–1426.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li H, Gao RL, Adeyemo O, Itkin M, Kaplan DE. Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clin Immunol. 2011;139:302–313.
   PubMed Web of Science ®Google Scholar
• Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. LIC. 2017;6:1–12.
   Google Scholar
• Heinrich B, Czauderna C, Marquardt JU. Immunotherapy of Hepatocellular Carcinoma. ORT. 2018;41:292–297.
   Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim T-Y, Choo S-P, Trojan J, Welling TH, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges. Oncologist. 2019;24:S3–S10.
   PubMed Web of Science ®Google Scholar
• Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol. 2018;35:4001.
   Google Scholar
• Bristol-Myers Squibb Announces Results from CheckMate. 459 study evaluating opdivo (nivolumab) as a first-line treatment for patients with unresectable hepatocellular carcinoma. 2019 June 24. [accessed 2019 Sep 20]. https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-459-study-evaluating-opdivo-nivol
   Google Scholar
• Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim H-Y, Breder VV, Edeline J, Chao Y, Ogasawara S, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37:4004.
   Web of Science ®Google Scholar
• Schubert M-L, Hoffmann J-M, Dreger P, Müller-Tidow C, Schmitt M. Chimeric antigen receptor transduced T cells: tuning up for the next generation. Int J Cancer. 2018;142:1738–1747.
   PubMed Web of Science ®Google Scholar
• Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. The Lancet. 2000;356:802–807.
   PubMed Web of Science ®Google Scholar
• Ma W, Wu L, Zhou F, Hong Z, Liu Z, Yuan Y. T cell–associated immunotherapy for hepatocellular carcinoma. CPB. 2017;41:609–622.
   Google Scholar
• Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann J-H, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells In vitro and in mice. Gastroenterology. 2015;149:1042–1052.
   PubMed Web of Science ®Google Scholar
• Zhu W, Peng Y, Wang L, Hong Y, Jiang X, Li Q, Liu H, Huang L, Wu J, Celis E, et al. Identification of α-fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy. Hepatology. 2018;68:574–589.
   Web of Science ®Google Scholar
• Sun L, Guo H, Jiang R, Lu L, Liu T, He X. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumor Biol. 2015;37:799–806.
   PubMedGoogle Scholar
• Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8:573–589.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Brunetto M, Maini MK, Bonino F, Qasim W, Stauss H. T cell receptor-therapy in HBV-related hepatocellularcarcinoma. Oncoimmunology. 2015;4:e1008354.
   PubMed Web of Science ®Google Scholar
• Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37:220–230.
   PubMed Web of Science ®Google Scholar
• Yeku O, Li X, Brentjens RJ. Adoptive T-cell therapy for solid tumors. Am Soc Clin Oncol Educ Book. 2017;37:193–204.
   PubMedGoogle Scholar
• Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T‐cell therapy of solid tumors. Immunol Cell Biol. 2017;95:356–363.
   PubMed Web of Science ®Google Scholar
• Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6:15772–15787.
   PubMedGoogle Scholar
• Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu N, Tian F, Wang F, Yuan J. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat. 2014;145:23–32.
   PubMed Web of Science ®Google Scholar
• Song X, Hao J, Wang J, Guo C, Wang Y, He Q, Tang H, Qin X, Li Y, Zhang Y, et al. The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling. Oncogene. 2017;36(11):1476.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA. 2012;109:5797–5802.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–924.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019–1027.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356:200–205.
   PubMed Web of Science ®Google Scholar
• Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JNM, de Man RA, Pan Q, Sleijfer S, Bruno MJ, et al. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer. 2015;112:1911–1920.
   PubMed Web of Science ®Google Scholar
• Li K, Y L, Wang J, Liu L. Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles. Tumor Biol. 2017;39:1010428317692229.
   Google Scholar
• Seifi-Alan M, Shamsi R, Ghafouri-Fard S. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. Immunotherapy. 2018;10:411–421.
   PubMed Web of Science ®Google Scholar
• Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina JD, Powell DJ, Riley J, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719–4730. clincanres.0351.2011
   PubMed Web of Science ®Google Scholar
• Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724–740.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6:261ra151.
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang W-C, Ostberg JR, Neman J, Jandial R, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clin Cancer Res. 2018;24:95–105.
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA, McCormack E, Wang LJ, Mooring JW, Point G, Khare PD, Thorn M, Ma Q, Stainken BF, et al. Phase I Hepatic Immunotherapy for Metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21(14):3149–3159. clincanres.1421.2014.
   PubMed Web of Science ®Google Scholar
• Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers (Basel). 2017;9:92.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620–626.
   PubMed Web of Science ®Google Scholar
• Liu D, Qi X, Manjunath Y, Kimchi ET, Ma L, Kaifi JT, Staveley-O’Carroll KF, Sunitinib LG. sorafenib modulating antitumor immunity in hepatocellular cancer. J Immunol Res Ther. 2018;3:115–123.
   PubMedGoogle Scholar
• Inada Y, Mizukoshi E, Seike T, Tamai T, Iida N, Kitahara M, Yamashita T, Arai K, Terashima T, Fushimi K, et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology. 2019;69:653–665.
   PubMed Web of Science ®Google Scholar
• Xu W, Liu K, Chen M, Sun J-Y, McCaughan GW, Lu X-J, Ji J. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol. 2019.
   Web of Science ®Google Scholar
• Wang L, Yan K, Zhou J, Zhang N, Wang M, Song J, Zhao J, Zhang Y, Cai S, Zhao Y, et al. Relationship of liver cancer with LRP1B or TP53 mutation and tumor mutation burden and survival. J Clin Oncol. 2019;37:1573.
   Google Scholar
• Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, Du G, Luo H, Wu X, Wang Y, et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front Pharmacol. 2018;9:1118.
   PubMed Web of Science ®Google Scholar
• Pan Z, Di S, Shi B, Jiang H, Shi Z, Liu Y, Wang Y, Luo H, Yu M, Wu X, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother. 2018;67:1621–1634.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, Kagaya T, Yamashita T, Fushimi K, Kaneko S. Enhancement of tumor‐associated antigen‐specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013;57:1448–1457.
   PubMed Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545–551.
   PubMed Web of Science ®Google Scholar
• DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelain M. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018;26:2542–2552.
   PubMed Web of Science ®Google Scholar
• Keane FK, Hong TS, Zhu AX. Evolving systemic therapy in hepatocellular carcinoma: current management and opportunities for integration with radiotherapy. Semin Radiat Oncol. 2018;28:332–341.
   PubMed Web of Science ®Google Scholar
• Textor A, Listopad JJ, Wührmann LL, Perez C, Kruschinski A, Chmielewski M, Abken H, Blankenstein T, Charo J. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ. Cancer Res. 2014;74:6796–6805.
   PubMed Web of Science ®Google Scholar
• Chino F, Pollis KE, Choi S, Salama JK, Palta M. Stereotactic body radiation therapy-induced abscopal effect on hepatocellular carcinoma after treatment for lung cancer: a case report. Hepatology. 2018;68:1653–1655.
   PubMed Web of Science ®Google Scholar
• Hong YK, Li Y, Pandit H, Li S, Pulliam Z, Zheng Q, Yu Y, Martin RCG. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. Cell Immunol. 2019;336:66–72.
   PubMed Web of Science ®Google Scholar